Literature DB >> 19640753

Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa.

Shawn E Lipinski1, Michael J Lipinski, Autumn Burnette, Thomas A Platts-Mills, William G Wilson.   

Abstract

We report on the successful desensitization of an adult female with Pompe disease who had previously experienced anaphylaxis to intravenous alglucosidase alfa therapy. The starting alglucosidase alfa dose for desensitization was 10mg/kg with gradual dose escalation and desensitization via serial dilution was completed over five infusions. This methodology serves as a means to desensitize patients with prior anaphylactic response to alglucosidase alfa so that enzyme replacement therapy can be utilized.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19640753     DOI: 10.1016/j.ymgme.2009.07.001

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  8 in total

1.  Immune Modulation Therapy in a CRIM-Positive and IgG Antibody-Positive Infant with Pompe Disease Treated with Alglucosidase Alfa: A Case Report.

Authors:  Josko Markic; Branka Polic; Radenka Kuzmanic-Samija; Eugenija Marusic; Luka Stricevic; Vitomir Metlicic; Julije Mestrovic
Journal:  JIMD Rep       Date:  2011-09-06

Review 2.  Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.

Authors:  Kenneth J Valenzano; Richie Khanna; Allan C Powe; Robert Boyd; Gary Lee; John J Flanagan; Elfrida R Benjamin
Journal:  Assay Drug Dev Technol       Date:  2011-06       Impact factor: 1.738

3.  Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study.

Authors:  Josko Markic; Branka Polic; Luka Stricevic; Vitomir Metlicic; Radenka Kuzmanic-Samija; Tanja Kovacevic; Ivana Erceg Ivkosic; Julije Mestrovic
Journal:  Wien Klin Wochenschr       Date:  2013-12-14       Impact factor: 1.704

4.  Successful Desensitisation in a Patient with CRIM-Positive Infantile-Onset Pompe Disease.

Authors:  J Baruteau; A Broomfield; V Crook; N Finnegan; K Harvey; D Burke; M Burch; G Shepherd; A Vellodi
Journal:  JIMD Rep       Date:  2013-09-04

5.  An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions.

Authors:  Areeg H El-Gharbawy; Joanne Mackey; Stephanie DeArmey; Greg Westby; Sherry G Grinnell; Peggy Malovrh; Robert Conway; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2011-07-13       Impact factor: 4.797

6.  Administration of anti-CD3 antibodies modulates the immune response to an infusion of α-glucosidase in mice.

Authors:  Toya Ohashi; Sayoko Iizuka; Yohta Shimada; Takashi Higuchi; Yoshikatsu Eto; Hiroyuki Ida; Hiroshi Kobayashi
Journal:  Mol Ther       Date:  2012-08-07       Impact factor: 11.454

7.  Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.

Authors:  Elisa Masat; Pascal Laforêt; Marie De Antonio; Guillaume Corre; Barbara Perniconi; Nadjib Taouagh; Kuberaka Mariampillai; Damien Amelin; Wladimir Mauhin; Jean-Yves Hogrel; Catherine Caillaud; Giuseppe Ronzitti; Francesco Puzzo; Klaudia Kuranda; Pasqualina Colella; Roberto Mallone; Olivier Benveniste; Federico Mingozzi
Journal:  Sci Rep       Date:  2016-11-04       Impact factor: 4.379

Review 8.  Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel.

Authors:  Vincenza Gragnaniello; Federica Deodato; Serena Gasperini; Maria Alice Donati; Clementina Canessa; Simona Fecarotta; Antonia Pascarella; Giuseppe Spadaro; Daniela Concolino; Alberto Burlina; Giancarlo Parenti; Pietro Strisciuglio; Agata Fiumara; Roberto Della Casa
Journal:  Ital J Pediatr       Date:  2022-03-05       Impact factor: 2.638

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.